Phaseline

Companies › Prilenia

Prilenia: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 2 Phase 3, 1 Phase 2; Neurology; next expected readout Mar 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Pridopidine
Dopamine D2 receptor modulator
DRD2Phase 3Amyotrophic Lateral Sclerosis; Huntington DiseaseMar 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04297683PridopidinePhase 2Amyotrophic Lateral SclerosisNeurologyJul 2027
NCT07322003PridopidinePhase 3Amyotrophic Lateral SclerosisNeurologyMar 2028
NCT07609108PridopidinePhase 3Huntington DiseaseNeurologyJun 2028

Targets

DRD2 (1)

Companies with the same targets

Changchun GeneScience Pharmaceutical Vanda Pharmaceuticals Intra-Cellular Therapies LB Pharmaceuticals Sichuan Kelun Pharmaceutical Gedeon Richter Jazz Pharmaceuticals Serina Therapeutics Boryung Pharmaceutical Anxo Pharmaceutical

Companies built like this

MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals Ambros Therapeutics Cerevance Green Valley (Shanghai) Pharmaceuticals CereMark Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.